References
- Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagno-sis and treatment. Mayo Clin Proc 2005; 80: 1087–97.
- Gisselbrecht C, Mounier N. Improving second-line therapy in aggressive non-Hodgkin's lymphoma. Semin Oncol 2004; 31(1 Suppl 2):12-6.
- Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for fol-licular lymphoma, diffuse large cell lymphoma and Hodgkin dis-ease. Brit J Haematol 2006; 133: 3–18.
- Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–5.
- Kluin-Nelemans HC. Autologous stem cell transplantation in treatment of aggressive non-Hodgkin's lymphoma. Croat Med J 2002; 43: 561–4.
- Reiser M, Bredenfeld H, Engert A, Diehl V. The role of ifosfamide in the treatment of relapsed and refractory lymphoma. Eur J Haematol 2001; 66 (Suppl. 64):37-40.
- Velasquez WS, Cabanillas F, Salvador P et al. Effective sal-vage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–22.
- Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood, 1982; 60: 693–697
- Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for trans-plant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-85.
- De Lord C, Newland AC, Linch DC, Vaughan Hudson B, Vaughan Hudson G. Failure of IMVP-16 as second line treat-ment for relapsed or refractory high-grade non-Hodgkin's lym-phoma. Haematol Oncol 1992; 10: 81–6.
- Aurer I, Durakovi N, Radman I et al. Combination of ifos-famide, methotrexate, and etoposide (IMVP) as a salvage ther-apy for relapsed and refractory aggressive non-Hodgkin lym-phoma: retrospective study. Croat Med J 2002; 43: 550–4.
- http://ctep.cancer.gov
- Cheson BD, Horning SJ, Coiffier B et al. Report of an in-ternational workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–53.
- Nemet D, Radman I, Aurer I et al. High-dose ifosfamide and mitoxantrone as cytoreductive and mobilization protocol for relapsed and refractory lymphoma. Blood 2003; 102: 416b-417b.
- Nemet D. Autologous hematopoietic stem cell transplan-tation in the treatment of malignant lymphomas. Lije Vjesn 1999; 121 (Suppl. 3):94-9.
- The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–94.
- Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006; 17 (Suppl.4): iv25-iv30.
- Itoh K, Igarashi T, Ohtsu T et al. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Int J Hematol 1998; 68: 431–7.
- Jerkeman M, Leppä S, Kvaloy S, Holte H. ICE (ifos-famide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma — the Nordic Lymphoma Group experience. Eur J Haematol 2004; 73: 179–82.
- The non-Hodgkin's lymphoma classification project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–18.
- Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell trans-plantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–8.
- Vellenga E, Notenboom A, van 't Veer M et al. Rituximab (Mabthera) improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL. A prospective randomized HOVON trial. Blood 2006; 108 (abstr.328).
- Hagberg H, Gisselbrecht C, CORAL study group. Ran-domised phase III study of R-ICE versus R-DHAP in relapsed pa-tients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17 (Suppl. 4): iv 31-2.